RAPID Reserve Act
- Bill Number
- S. 2062
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-12: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-01-14T05:02:29Z
AI-Generated Summary
Purpose
The Rolling Active Pharmaceutical Ingredient and Drug Reserve Act (RAPID Reserve Act) aims to strengthen the resilience of the U.S. drug supply chain by creating a program to maintain reserves of critical drugs and their active pharmaceutical ingredients (APIs, which are the key chemical components that make drugs effective). It focuses on drugs with weak or "vulnerable" supply chains to prevent shortages during public health emergencies, natural disasters, or other threats like chemical, biological, radiological, or nuclear events.
Key Provisions
- Establishment of the Reserve Program: The Secretary of Health and Human Services (HHS) must award contracts or cooperative agreements to qualified organizations (eligible entities) for drugs and APIs identified as critical with vulnerable supply chains. HHS will publish a public list of these items.
- Reserve Requirements: Eligible entities must:
- Maintain a 6-month supply (or another amount set by HHS) of both the API and the finished drug product in approved facilities (either in the U.S. or in countries belonging to the Organisation for Economic Co-operation and Development, or OECD, which includes nations like Canada, Japan, and most of Europe).
- Regularly refresh these reserves with newly made supplies.
- Ramp up production of the drug or API when directed by HHS.
- Share portions of reserves with other manufacturers if needed to address shortages, or allow HHS to redirect them during emergencies.
- Guidance and Preferences: Within 180 days of the law's enactment, HHS, working with the Food and Drug Administration (FDA), must issue guidelines on:
- How to identify vulnerable supply chains (e.g., reliance on few manufacturers or geographic concentration of production).
- What makes an entity eligible (e.g., strong quality controls, manufacturing experience, and commitment to U.S.-based production).
- Contract rules, including requirements for extra production capacity and quality systems.
- Awards must prioritize U.S.-based manufacturing or sourcing from OECD countries, while promoting competition, quality, and cost efficiency.
- Contract Flexibility: Contracts can include funding for building or upgrading facilities to boost emergency preparedness, even for non-government-owned sites.
- Definitions:
- Eligible Drug: A FDA-approved or licensed drug vital for emergencies, where shortages could harm the healthcare system or vulnerable groups, and with supply risks like complex production or safety issues.
- Eligible Entity: Drug approval holders, API makers, or distributors with U.S. or OECD facilities and a history of good manufacturing practices (standards ensuring safe, high-quality production).
- Reporting and Funding: HHS must report to Congress every two years on selected drugs and program effectiveness (without revealing sensitive security details). The law authorizes $500 million for fiscal year 2026 to fund the program.
Significant Changes to Existing Law
This bill introduces a new federal program under HHS authority, building on the Federal Food, Drug, and Cosmetic Act (which governs drug approvals and manufacturing) but adding requirements for mandatory reserves and production surges not previously mandated. It expands HHS's role in supply chain management without directly amending prior laws, though it references and aligns with existing shortage definitions and registration rules for drug facilities.
Potential Impacts
- Government Agencies: HHS and FDA will gain new responsibilities for identifying risks, awarding contracts, and overseeing reserves, potentially increasing administrative workload but improving coordination with public health entities like the Centers for Disease Control and Prevention (CDC).
- Citizens: Could reduce drug shortages, ensuring more reliable access to essential medications during crises, benefiting patients with serious illnesses or in at-risk communities.
- International Relations: Encourages shifting production toward the U.S. or allied OECD nations, which may reduce dependence on non-OECD suppliers (e.g., in Asia) and strengthen ties with OECD partners, but could strain relations with countries outside this group if supply chains are disrupted.
Main Stakeholders Affected
- Pharmaceutical Companies and Manufacturers: Drug makers, API producers, and distributors who qualify as eligible entities; they must invest in reserves and capacity but gain contracts and preferences for domestic operations.
- Government Entities: HHS, FDA, CDC, and the Assistant Secretary for Preparedness and Response, who will implement and monitor the program.
- Healthcare Providers and Patients: Hospitals, clinics, and individuals relying on critical drugs, who stand to benefit from fewer disruptions.
- Congress and Taxpayers: Oversees funding and reporting; the $500 million authorization involves public spending to support industry.
Notable Legal, Constitutional, or Political Implications
- Legal: Relies on HHS's existing regulatory powers over drugs but introduces enforceable contracts with penalties implied through award conditions; potential challenges could arise over definitions of "vulnerable" supply chains if seen as arbitrary.
- Constitutional: Uses Congress's spending power to incentivize private-sector actions, which is standard but could face scrutiny if viewed as overreach into commerce (e.g., mandating reserves).
- Political: Bipartisan sponsorship (Democrats and Republicans) signals broad support for health security; emphasizes domestic manufacturing, aligning with national security priorities without overt trade restrictions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Sen. Blackburn, Marsha [R-TN], Sen. Budd, Ted [R-NC], Sen. Kaine, Tim [D-VA]
Recent Actions
- 2025-06-12: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-06-12: Introduced in Senate
Bill Versions
- Rolling Active Pharmaceutical Ingredient and Drug Reserve Act — issued 2025-06-12 — PDF (11 pages)